XML 33 R20.htm IDEA: XBRL DOCUMENT
v3.23.3

Earnings (Loss) Per Share | 9 Months Ended
--- | ---
Sep. 30, 2023
Earnings Per Share [Abstract] |
Earnings (Loss) Per Share | Earnings (Loss) Per Share Earnings (loss) per share is computed using the treasury stock method. For periods in which the Company reports net income, diluted earnings per share is determined using the weighted average number of common and dilutive common equivalent shares outstanding during the period, unless the effect is antidilutive. Stock options and stock appreciation rights to purchase 9 million and 7 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share for the three and nine months ended September 30, 2023, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, stock options and stock appreciation rights to purchase 4 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings (loss) per share for each of the three and nine-month periods ended September 30, 2022. In addition, due to the net loss attributable to CVS Health in the three months ended September 30, 2022, 8 million potentially dilutive common equivalent shares were excluded from the calculation of diluted loss per share, as the impact of these shares was antidilutive for that period. The following is a reconciliation of basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2023 and 2022:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
In millions, except per share amounts | 2023 |  | 2022 |  | 2023 |  | 2022
Numerator for earnings (loss) per share calculation: |  |  |  |  |  |  |
Net income (loss) attributable to CVS Health | $ | 2,261 |  |  | $ | (3,406) |  |  | $ | 6,298 |  |  | $ | 1,977 |
Denominator for earnings (loss) per share calculation: |  |  |  |  |  |  |
Weighted average shares, basic | 1,287 |  |  | 1,315 |  |  | 1,284 |  |  | 1,313 |
Restricted stock units and performance stock units | 2 |  |  | — |  |  | 3 |  |  | 6 |
Stock options and stock appreciation rights | 1 |  |  | — |  |  | 2 |  |  | 5 |
Weighted average shares, diluted | 1,290 |  |  | 1,315 |  |  | 1,289 |  |  | 1,324 |
Earnings (loss) per share: |  |  |  |  |  |  |
Basic | $ | 1.76 |  |  | $ | (2.59) |  |  | $ | 4.90 |  |  | $ | 1.51 |
Diluted | $ | 1.75 |  |  | $ | (2.59) |  |  | $ | 4.88 |  |  | $ | 1.49 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration